Protein Serine/Threonine Kinases in Neurodegenerative Disorders discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. The book introduces protein kinases and inhibitors and includes detailed discussions on different types of kinases, including protein kinase C (PKC), AMP-activated protein kinase (AMPK), death-associated protein kinase 1 (DAPK1), cyclin-dependent kinases (CDKs), glycogen synthase kinases (GSKs), Rho-associated protein kinase (ROCK), microtubule affinity regulating kinases (MARKs), mammalian target of rapamycin (mTOR), leucine-rich repeat kinase 2 (LRRK2), PTEN-induced kinase 1 (PINK1), and dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), and their roles in neurodegenerative disease, potential inhibitors, and therapeutic mechanisms.
This book features 23 chapters written by renowned experts in the field of kinases. It explores novel targets modulated by protein kinases, including noncoding RNAs (ncRNAs) and mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases, and their roles in neurodegeneration. It also discusses the nexus between glycogen synthase kinases (GSKs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role of metabolic regulation in neurodegeneration. The modulatory effects of protein kinase B (PKB/AKT) pathways in various neurodegenerative disorders, particularly Parkinson’s disease, are also examined. This book sheds light on bioactive compounds from natural products that target kinases and explains the role of different kinases in various pathogenic pathways and mechanisms involved in neurodegeneration, including regulated cell death, autophagy, synaptic dysfunction, and neuroinflammation.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xi 8. About the editors - p. xv 9. Preface - p. xvii 10. Acknowledgment - p. xix 11. Chapter 1. Protein serine/threonine kinases: an overview - p. 1 12. Chapter 2. Protein kinase C in neurodegenerative disorders - p. 19 13. Chapter 3. AMP-activated protein kinase in neurodegenerative disorders - p. 53 14. Chapter 4. Death-associated protein kinase 1 in neurodegenerative disorders - p. 65 15. Chapter 5. The mitogen-activated protein kinases activated by tyrosine receptor kinases (Trk receptors for neurotrophin) and their roles in neurodegeneration - p. 83 16. Chapter 6. Cyclin-dependent kinases in neurodegenerative disorders - p. 109 17. Chapter 7. Unlocking the potential of GSK-3β inhibitors in neurodegenerative disease prognosis: insights from glucagon-like peptide-1 receptor agonist effects - p. 121 18. Chapter 8. Rho-associated coiled-coil containing protein kinase (ROCK) in neurodegenerative disorders - p. 133 19. Chapter 9. Microtubule affinity-regulating kinases in neurodegenerative disorders - p. 155 20. Chapter 10. Mechanistic target of rapamycin in neurodegenerative disorders - p. 185 21. Chapter 11. Leucine-rich repeat kinase 2: a potential target in Parkinson’s disease and beyond - p. 203 22. Chapter 12. PTEN-induced kinase 1 in neurodegenerative disorders - p. 223 23. Chapter 13. Dual-specificity tyrosine phosphorylation-regulated kinase 1A in neurodegenerative disorders - p. 235 24. Chapter 14. The protein kinase B pathway as therapeutic target in neurodegenerative diseases: mechanisms and implications - p. 253 25. Chapter 15. Targeting Protein Kinase B (AKT) pathways: a potential therapeutic target for Parkinson's disease - p. 297 26. Chapter 16. Noncoding RNAs regulating serine/threonine kinases in neurodegeneration - p. 317 27. Chapter 17. Protein serine/threonine signaling pathways: opportunities and translational perspectives - p. 339 28. Chapter 18. Natural products in neurodegenerative diseases: role of serine/threonine kinases - p. 357 29. Chapter 19. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders - p. 395 30. Chapter 20. Targeting regulated cell death-related serine/threonine kinases to combat neurodegenerative disorders - p. 413 31. Chapter 21. Splicing kinases in neuronal health and neurodegeneration - p. 461 32. Chapter 22. Balancing efficacy and safety: protein kinase inhibitors and drug-induced liver injury - p. 521 33. Chapter 23. Targeting serine/threonine kinases: therapeutic innovations for neurodegenerative disorders - p. 537 34. Index - p. 559
Protein Serine/Threonine Kinases in Neurodegenerative Disorders discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. The book introduces protein kinases and inhibitors and includes detailed discussions on different types of kinases, including protein kinase C (PKC), AMP-activated protein kinase (AMPK), death-associated protein kinase 1 (DAPK1), cyclin-dependent kinases (CDKs), glycogen synthase kinases (GSKs), Rho-associated protein kinase (ROCK), microtubule affinity regulating kinases (MARKs), mammalian target of rapamycin (mTOR), leucine-rich repeat kinase 2 (LRRK2), PTEN-induced kinase 1 (PINK1), and dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), and their roles in neurodegenerative disease, potential inhibitors, and therapeutic mechanisms.
This book features 23 chapters written by renowned experts in the field of kinases. It explores novel targets modulated by protein kinases, including noncoding RNAs (ncRNAs) and mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases, and their roles in neurodegeneration. It also discusses the nexus between glycogen synthase kinases (GSKs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role of metabolic regulation in neurodegeneration. The modulatory effects of protein kinase B (PKB/AKT) pathways in various neurodegenerative disorders, particularly Parkinson’s disease, are also examined. This book sheds light on bioactive compounds from natural products that target kinases and explains the role of different kinases in various pathogenic pathways and mechanisms involved in neurodegeneration, including regulated cell death, autophagy, synaptic dysfunction, and neuroinflammation.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xi 8. About the editors - p. xv 9. Preface - p. xvii 10. Acknowledgment - p. xix 11. Chapter 1. Protein serine/threonine kinases: an overview - p. 1 12. Chapter 2. Protein kinase C in neurodegenerative disorders - p. 19 13. Chapter 3. AMP-activated protein kinase in neurodegenerative disorders - p. 53 14. Chapter 4. Death-associated protein kinase 1 in neurodegenerative disorders - p. 65 15. Chapter 5. The mitogen-activated protein kinases activated by tyrosine receptor kinases (Trk receptors for neurotrophin) and their roles in neurodegeneration - p. 83 16. Chapter 6. Cyclin-dependent kinases in neurodegenerative disorders - p. 109 17. Chapter 7. Unlocking the potential of GSK-3β inhibitors in neurodegenerative disease prognosis: insights from glucagon-like peptide-1 receptor agonist effects - p. 121 18. Chapter 8. Rho-associated coiled-coil containing protein kinase (ROCK) in neurodegenerative disorders - p. 133 19. Chapter 9. Microtubule affinity-regulating kinases in neurodegenerative disorders - p. 155 20. Chapter 10. Mechanistic target of rapamycin in neurodegenerative disorders - p. 185 21. Chapter 11. Leucine-rich repeat kinase 2: a potential target in Parkinson’s disease and beyond - p. 203 22. Chapter 12. PTEN-induced kinase 1 in neurodegenerative disorders - p. 223 23. Chapter 13. Dual-specificity tyrosine phosphorylation-regulated kinase 1A in neurodegenerative disorders - p. 235 24. Chapter 14. The protein kinase B pathway as therapeutic target in neurodegenerative diseases: mechanisms and implications - p. 253 25. Chapter 15. Targeting Protein Kinase B (AKT) pathways: a potential therapeutic target for Parkinson's disease - p. 297 26. Chapter 16. Noncoding RNAs regulating serine/threonine kinases in neurodegeneration - p. 317 27. Chapter 17. Protein serine/threonine signaling pathways: opportunities and translational perspectives - p. 339 28. Chapter 18. Natural products in neurodegenerative diseases: role of serine/threonine kinases - p. 357 29. Chapter 19. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders - p. 395 30. Chapter 20. Targeting regulated cell death-related serine/threonine kinases to combat neurodegenerative disorders - p. 413 31. Chapter 21. Splicing kinases in neuronal health and neurodegeneration - p. 461 32. Chapter 22. Balancing efficacy and safety: protein kinase inhibitors and drug-induced liver injury - p. 521 33. Chapter 23. Targeting serine/threonine kinases: therapeutic innovations for neurodegenerative disorders - p. 537 34. Index - p. 559
